Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine"

Transcription

1 Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine

2 Setting the scene GB, 43 yo AA man followed for hypothyroidism returns on LT4 125 mcg/d and has a TSH=1.1 mu/l. Weight has increased from over the last 18 months. He is 5 10 (BMI=29); waist circumference is 42 ; BP=130/85 Fasting lipids: Tg = 178 mg/dl, HDL = 36 mg/dl, LDL =129 mg/dl, fasting glucose= 112 mg/dl

3 The response Physician: You need to lose weight Patient: You look overweight yourself. Why do I need to lose weight?

4 Cardiovascular risk: Framingham Sex Blood pressure Cholesterol Diabetes Smoking

5 Cardiovascular risk: Framingham Sex Blood pressure Cholesterol Smoking Diabetes 1991: Risk prediction model

6 Addressing Unaddressed classical risk: risk statins factors events (%) LDL (mg/dl) Statin placebo 20-25% risk reduction Persistent risk Years of follow-up Benefit/1000 (SE): 5(3) 20(4) 35(5) 46(5) 54(7) 60(18) Heart Protection Study, Lancet 2002

7 The evolving landscape

8 Cardiovascular disease: the landscape since Framingham No Data <10% <10% 10% 14% 10% 14% 15% 19% 15% 19% 20% 24% 20% 24% 25-29% 30% 25% Mokdad et al., BRFSS CDC

9 Cardiovascular burden of obesity CVD deaths (thousands) The new landscape Diabetes Deaths (thousands) Source: NCHS and CDC

10 Why is obesity bad? Resistin Adiponectin The endocrine adipocyte. Bone Morphogenic Protein IGF-1 IGFBP TNF-α Interleukins TGF β FGF EGF Fatty Acids Lactate Adenosine Prostaglandins Glutamine Unknown Factors Estrogen Ang II Angiotensinogen Leptin PAI-1 Adapted from: Roth, J, et al, Obesity Research, Vol 12, supplement Nov 2004:88S-101S

11 Good fat bad fat?? Abdominal (Android) Lower Body (Gynoid)

12 Metabolic Syndrome Hypertension C-II C-III B-100 and Triglyceride VLDL HDL cholesterol Small dense LDL Glucose FFA Interleukin 6 Insulin Sympathetic nervous system C-reactive protein TNF Interleukin 6 Insulin Glycogen FFA FFA CO 2 Fibrinogen PAI-1 Adiponectin Eckel Lancet Prothrombic state Triglyceride (intramuscular droplet)

13 Metabolic syndrome Conceptualization An insulin resistance disorder An inflammatory disorder A prothrombotic disorder A controversial disorder Resulting in increased cardiometabolic risk

14 Metabolic Syndrome: ATP III 3 or more of the following: Central obesity as measured by waist circumference: Men Greater than or equal to 40 inches Women Greater than or equal to 35 inches Fasting blood triglycerides greater than or equal to 150 mg/dl Blood HDL cholesterol: Men Less than 40 mg/dl Women Less than 50 mg/dl Blood pressure greater than or equal to 130/85 mmhg Fasting glucose greater than or equal to 100 mg/dl

15 What is Cardiometabolic Risk? Beyond Framingham Type 2 Diabetes Elevated Blood Pressure Smoking Elevated LDL Elevated Blood Glucose Inflammatory Markers Abdominal Adiposity Elevated Triglycerides Low HDL Insulin Resistance CVD

16 Does metabolic syndrome increase morbidity or mortality? prevalence (%) mortality (%)20 0 stroke MI CHD 0 all cause CHD without metabolic syndrome with metabolic syndrome WHO criteria, Botnia cohort, Isomaa, Diabetes Care 2001

17 Obesity correlates with (and we are learning, causes): Insulin resistance Hypertension Dyslipidemia Diabetes Inflammation Impaired fibrinolysis

18 Increased adiposity yields insulin resistance and risk of diabetes (dramatically) body weight (kg) plasma insulin (µu/ml) blood glucose (mg/dl) time (min) time (min) Genuth, Ann. Int. Med. 1977

19 Visceral adiposity is correlated with peripheral insulin resistance Insulin-mediated glucose disposal (mg/kg lean body mass/min) p< Visceral adipose tissue volume (L) Banerji MA et al. J Clin Endocrinol Metab. 1999;84:

20 Inherent risk: diabetes dyslipidemia 7-Year Incidence of Fatal/Nonfatal MI Nondiabetic Diabetic P<0.001 WOW! P< Incidence (%) n = 1304 n = 69 n = 890 n = 169 No DM, No MI n = 1304 No DM, MI n = 69 DM, No MI n = 890 DM, MI n = 169 Haffner SM et al. N Engl J Med. 1998;339:

21 Obesity and cardiometabolic risk GB, 43 yo AA man followed for hypothyroidism returns on LT4 125 mcg/d and has a TSH=1.1 mu/l. Weight has increased from over the last 18 months. He is 5 10 (BMI=29); waist circumference is 42 ; BP=130/85 Fasting lipids: Tg = 178 mg/dl, HDL = 36 mg/dl, LDL =129 mg/dl, fasting glucose= 112 mg/dl

22 Obesity dyslipidemia Hypertension C-II C-III B-100 and Triglyceride VLDL HDL cholesterol Small dense LDL Glucose FFA Interleukin 6 Insulin Sympathetic nervous system C-reactive protein TNF Interleukin 6 Insulin Glycogen FFA FFA CO 2 Fibrinogen PAI-1 Adiponectin Eckel Lancet Prothrombic state Triglyceride (intramuscular droplet)

23 Obesity dyslipidemia Hypercholesterolemia Hypertriglyceridemia Low and abnormal HDL cholesterol Abnormal LDL cholesterol

24 Insulin resistance and hypertriglyceridemia Plasma TG (mg/dl) r = 0.73 P < Insulin Response to Oral Glucose* * Total area under 3-hour response curve (mean of 2 tests). Olefsky JM et al. Am J Med. 1974;57:

25 Obesity dyslipidemia Insulin FFA Liver TG

26 Plasma insulin, triglycerides and ischemic heart disease Quebec Cardiovascular Study Odds Ratio p= P=0.002 < >15 F-Insulin (µu/ml) Despres JP et al. N Engl J Med 1996;334: P<0.001 p= Triglycerides >150 mg/dl <150 mg/dl

27 Obesity dyslipidemia Fat Cells FFA Liver CE IR X Insulin TG ApoB VLDL CE VLDL (CETP) TG (CETP) TG LDL HDL SD LDL (hepatic lipase) Apo A-1 Kidney (lipoprotein or hepatic lipase) Lipids online (Ginsberg)

28 Is hepatic VLDL production a therapeutic target? Increasingly triglycerides are recognized as a cardiovascular risk factor VA-HIT, Helsinki Heart, Physicians Health study, EPIC-Norfolk Diabetics: WHO MSVDD Elderly, known CAD: CARE

29 Obesity and cardiometabolic risk GB, 43 yo AA man followed for hypothyroidism returns on LT4 125 mcg/d and has a TSH=1.1 mu/l. Weight has increased from over the last 18 months. He is 5 10 (BMI=29); waist circumference is 42 ; BP=130/85 Fasting lipids: Tg = 178 mg/dl, HDL = 36 mg/dl, LDL =129 mg/dl, fasting glucose= 112 mg/dl

30 Obesity, hypertension, and fibrinolysis Muniyappa, Endocr. Rev. 28(5): 463.

31 Insulin Blood flow (shear stress) Acetylcholine Endothelial function PI3K pathway Vasodilation PI3K Anti-atherogenic enos BH 4 Endothelial cell P enos CaM Ca 2+ PGIS Thrombolysis Other effects? Prostacyclin NO Vascular smooth muscle cell Rask-Madsen. Nat. Clin. Pract. Endocrinol. Metab. 2007; 3:46-56.

32 enos and hypertension Pharmacological inhibition of enos (n=7): 109(5)/65(3) 133(9)/79(5) Carotid wall stiffness 9.8(1.2) 12.6(2.0) Sugawara et al., Hypertension Res. 30(5) 2007

33 Hyperglycemia Free fatty acids Angiotensin II Insulin Endothelial dysfunction enos BH 2 NOX O 2 NO PKC ONOO PI3K pathway Selective insulin resistance N enos PGIS uncoupling Prostacyclin Endothelial cell synthase nitrosylation Thromboxane MAPK pathway ET-1 ET-1 Angiotensin II Vasoconstriction Smooth muscle proliferation Pro-atherotic Vascular smooth muscle cell Rask-Madsen. Nat. Clin. Pract. Endocrinol. Metab. 2007; 3:46-56.

34 Obesity and cardiometabolic risk GB, 43 yo AA man followed for hypothyroidism returns on LT4 125 mcg/d and has a TSH=1.1 mu/l. Weight has increased from over the last 18 months. He is 5 10 (BMI=29); waist circumference is 42 ; BP=130/85 Fasting lipids: Tg = 178 mg/dl, HDL = 36 mg/dl, LDL =129 mg/dl, fasting glucose= 112 mg/dl

35 Coagulation and Fibrinolysis Coagulation Factors Fibrinogen Fibrin t-pa, Urokinase Plasminogen PAI-1 Plasmin Lp(a) Fibrinolysis Homocysteine Cysteine Glutathione Lipids Online (Wilson)

36 PAI-1 increases with BMI Skurk, Int. J. of Obesity 2004

37 Insulin resistance as the defining lesion of metabolic syndrome Tissue Insulin effect Resistance Mechanism Brain Reduce food intake Increased food intake NPY/POMC Liver Suppress HGP Hyperglycemia Glycogenolysis/ GNG Fat Inhibit lipolysis/tg lipolysis/inc FFA HSL Endothelium Vasodilation dysfunction / hypertension PI3K-eNOS

38 Why insulin (and glucose)? Norhammer et al., (Lancet 2002) prospectively studied 181 acute MIs with no prior diagnosis of diabetes: -31% IGT -35% diabetes

39 Conclusions Obesity is associated with: Insulin resistance Inflammation Impaired fibrinolysis And: Hypertension Dyslipidemia Diabetes Cardiovascular disease Mechanisms involved are increasingly coming to light

The Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk

The Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk Update 2013 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine Denver Health

More information

Metabolic Syndrome in Asians

Metabolic Syndrome in Asians Metabolic Syndrome in Asians Alka Kanaya, MD Asst. Professor of Medicine, UCSF Asian CV Symposium, November 17, 2007 The Metabolic Syndrome Also known as: Syndrome X Insulin Resistance Syndrome The Deadly

More information

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories

More information

Pathophysiology of Lipid Disorders

Pathophysiology of Lipid Disorders Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history

More information

Adipose Tissue as an Endocrine Organ. Abdel Moniem Ibrahim, MD Professor of Physiology Cairo University

Adipose Tissue as an Endocrine Organ. Abdel Moniem Ibrahim, MD Professor of Physiology Cairo University Adipose Tissue as an Endocrine Organ Abdel Moniem Ibrahim, MD Professor of Physiology Cairo University Functions of Adipose Tissue Adipose tissue expresses and secretes a variety of bioactive peptides,

More information

Plasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension

Plasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original

More information

Metabolic syn and CVD. Dr : dehestani Imam reza hospital

Metabolic syn and CVD. Dr : dehestani Imam reza hospital Metabolic syn and CVD { Dr : dehestani Imam reza hospital Global Distribution of CVDs as Causes of Death, WHO 2011 Worldwide Mortality from Ischemic Heart Disease and Cerebrovascular Disease 2011 Ischemic

More information

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:

More information

Macrovascular Disease in Diabetes

Macrovascular Disease in Diabetes Macrovascular Disease in Diabetes William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research Conflicts CPC Clinical Research (University-based

More information

The Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk

The Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine

More information

Joslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia

Joslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,

More information

The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease

The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease Steve Smith, Group Director Scientific Affairs, Diabetes & Metabolism GlaxoSmithKline R & D

More information

Objectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015

Objectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015 Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015 Presentation downloaded from http://ce.unthsc.edu Objectives Understand that the obesity epidemic is also affecting children and adolescents

More information

Diabetes and Heart Disease. Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center

Diabetes and Heart Disease. Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center Diabetes and Heart Disease Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center No conflicts of interest or financial relationships to disclose. 2 What s the problem??

More information

Dyslipidemia Endothelial dysfunction Free radicals Immunologic

Dyslipidemia Endothelial dysfunction Free radicals Immunologic ATHEROSCLEROSIS Hossein Mehrani Professor of Clinical Biochemistry Definition Atherosclerosis: Is a chronic inflammatory process characterized by plaque formation within the vessel wall of arteries and

More information

The American Diabetes Association estimates

The American Diabetes Association estimates DYSLIPIDEMIA, PREDIABETES, AND TYPE 2 DIABETES: CLINICAL IMPLICATIONS OF THE VA-HIT SUBANALYSIS Frank M. Sacks, MD* ABSTRACT The most serious and common complication in adults with diabetes is cardiovascular

More information

Aggressive Lipid Management for Diabetes

Aggressive Lipid Management for Diabetes Aggressive Lipid Management for Diabetes Practical Ways to Achieve Targets in Diabetes Care Keystone, CO July 16, 2011 Robert H. Eckel, M.D. Professor of Medicine Professor of Physiology and Biophysics

More information

Epidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk. Eberhard Standl

Epidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk. Eberhard Standl Epidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk Eberhard Standl European Heart House Sophia Antipolis Thursday, June 17, 2010 IDF Diabetes Atlas 2009: Global Numbers Still

More information

Rick Fox M.A Health and Wellness Specialist

Rick Fox M.A Health and Wellness Specialist Metabolic Diseases Rick Fox M.A Health and Wellness Specialist Metabolic Diseases Metabolism is the process your body uses to get or make energy from the food you eat. Food is made up of proteins, carbohydrates

More information

KEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers

KEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers CardioMetabolic Risk Poor blood sugar regulation and unhealthy triglyceride and lipoprotein levels often present long before the diagnosis of type 2 Diabetes. SpectraCell s CardioMetabolic and Pre-Diabetes

More information

Know Your Number Aggregate Report Single Analysis Compared to National Averages

Know Your Number Aggregate Report Single Analysis Compared to National Averages Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics

More information

Diabetes Day for Primary Care Clinicians Advances in Diabetes Care

Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:

More information

Estrogens vs Testosterone for cardiovascular health and longevity

Estrogens vs Testosterone for cardiovascular health and longevity Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in

More information

Prof. John Chapman, MD, PhD, DSc

Prof. John Chapman, MD, PhD, DSc Prof. John Chapman, MD, PhD, DSc Director of the Dyslipidemia and Atherosclerosis Research Unit of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpétrière Hospital in Paris

More information

Before the Pre. PREDIABETES Diagnosis, Management, Treatment. A few thoughts on diabetes.

Before the Pre. PREDIABETES Diagnosis, Management, Treatment. A few thoughts on diabetes. PREDIABETES Diagnosis, Management, Treatment Before the Pre A few thoughts on diabetes. James Lenhard, MD Director, Diabetes and Metabolic Diseases Center Christiana Care Health System JLenhard@ChristianaCare.org

More information

ΛΟΙΜΩΞΗ HIV. Ιγνάτιος Οικονομίδης,MD,FESC Β Πανεπιστημιακή Καρδιολογική

ΛΟΙΜΩΞΗ HIV. Ιγνάτιος Οικονομίδης,MD,FESC Β Πανεπιστημιακή Καρδιολογική ΛΟΙΜΩΞΗ HIV Ιγνάτιος Οικονομίδης,MD,FESC Β Πανεπιστημιακή Καρδιολογική Κλινική, Νοσοκομείο «Αττικόν» Infection Acute Myocardial Infarction p er 100,000 HIV/AIDS discharg es 800 700 600 500 400 300 200

More information

Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology

Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the

More information

Chapter (5) Etiology of Low HDL- Cholesterol

Chapter (5) Etiology of Low HDL- Cholesterol Chapter (5) Etiology of Low HDL- Cholesterol The aim of this chapter is to summarize the different etiological factors mainly the role of life-style and different disease conditions contributing to the

More information

2/11/2017. Weighing the Heavy Cardiovascular Burden of Obesity and the Obesity Paradox. Disclosures. Carl J. Lavie, MD, FACC, FACP, FCCP

2/11/2017. Weighing the Heavy Cardiovascular Burden of Obesity and the Obesity Paradox. Disclosures. Carl J. Lavie, MD, FACC, FACP, FCCP Weighing the Heavy Cardiovascular Burden of Obesity and the Obesity Paradox Carl J. Lavie, MD, FACC, FACP, FCCP Professor of Medicine Medical Director, Cardiac Rehabilitation and Preventive Cardiology

More information

Case Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic

Case Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic Case Discussions: Treatment Strategies for High Risk Populations Peter H. Jones MD, FNLA Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Most Common Reasons for

More information

Metabolic Syndrome: Why Should We Look For It?

Metabolic Syndrome: Why Should We Look For It? 021-CardioCase 29/05/06 15:04 Page 21 Metabolic Syndrome: Why Should We Look For It? Dafna Rippel, MD, MHA and Andrew Ignaszewski, MD, FRCPC CardioCase presentation Andy s fatigue Andy, 47, comes to you

More information

3/25/2010. Age-adjusted incidence rates for coronary heart disease according to body mass index and waist circumference tertiles

3/25/2010. Age-adjusted incidence rates for coronary heart disease according to body mass index and waist circumference tertiles Outline Relationships among Regional Adiposity, Physical Activity, and CVD Risk Factors: Preliminary Results from Two Epidemiologic Studies Molly Conroy, MD, MPH Obesity Journal Club February 18, 2010

More information

Diabetes and Heart Disease

Diabetes and Heart Disease Diabetes and Heart Disease Sarah Alexander, MD Assistant Professor of Medicine Division of Cardiology Rush University Medical Center 2/8/2017 Rush is a not-for-profit health care, education and research

More information

EFFECTS OF WEIGHT LOSS ON VISCERAL ADIPOSITY AND METABOLIC ADAPTATIONS IN DIABETIC VERSUS NON- DIABETIC WOMEN

EFFECTS OF WEIGHT LOSS ON VISCERAL ADIPOSITY AND METABOLIC ADAPTATIONS IN DIABETIC VERSUS NON- DIABETIC WOMEN University of Kentucky UKnowledge University of Kentucky Doctoral Dissertations Graduate School 2005 EFFECTS OF WEIGHT LOSS ON VISCERAL ADIPOSITY AND METABOLIC ADAPTATIONS IN DIABETIC VERSUS NON- DIABETIC

More information

How to Reduce Residual Risk in Primary Prevention

How to Reduce Residual Risk in Primary Prevention How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with

More information

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION 2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL

More information

* Author to whom correspondence should be addressed; Tel.: ; Fax:

* Author to whom correspondence should be addressed;   Tel.: ; Fax: Int. J. Mol. Sci. 2014, 15, 6184-6223; doi:10.3390/ijms15046184 Review OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Obesity and Its Metabolic Complications:

More information

Berries and Cardiovascular Health

Berries and Cardiovascular Health Berries and Cardiovascular Health Britt Burton-Freeman, PhD Institute for Food Safety and Health Illinois Institute of Technology bburton@iit.edu Berry Health Benefits Symposium Westlake Village CA, 2011

More information

A Central Role of MG53 in Metabolic Syndrome. and Type-2 Diabetes

A Central Role of MG53 in Metabolic Syndrome. and Type-2 Diabetes A Central Role of MG53 in Metabolic Syndrome and Type-2 Diabetes Yan Zhang, Chunmei Cao, Rui-Ping Xiao Institute of Molecular Medicine (IMM) Peking University, Beijing, China Accelerated Aging in China

More information

New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines

New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines Clin. Cardiol. Vol. 26 (Suppl. III), III-19 III-24 (2003) New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines H. BRYAN BREWER, JR, M.D. Molecular

More information

1. Which one of the following patients does not need to be screened for hyperlipidemia:

1. Which one of the following patients does not need to be screened for hyperlipidemia: Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:

More information

CardioGenomicPlus Profile

CardioGenomicPlus Profile CardioGenomicPlus Profile Patient: SAMPLE PATIENT DOB: Sex: MRN: Apo E Chromosome 19 APOE APO E2: cys / cys APO E3: cys / arg APO E4: arg / arg The two SNPs lead to 3 possible variants for each chromosome,

More information

Interactions of exercise and diet in health prevention

Interactions of exercise and diet in health prevention Interactions of exercise and diet in health prevention Dr Jason Gill Institute of Cardiovascular and Medical Sciences University of Glasgow Physical activity and health outcomes does one size fit all?

More information

The IDF consensus worldwide definition of the metabolic syndrome

The IDF consensus worldwide definition of the metabolic syndrome International Diabetes Federation Avenue Emile De Mot 19 B-1000 Brussels, Belgium Telephone +32-2-5385511 Telefax +32-2-5385114 info@idf.org www.idf.org VAT BE433.674.528 The IDF consensus worldwide definition

More information

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE

More information

10/1/2008. Therapy? Disclosure Statement

10/1/2008. Therapy? Disclosure Statement What s New in Lipid Therapy? Brooke Hudspeth, PharmD Diabetes Care Kroger Pharmacy Disclosure Statement In accordance with policies set forth by the Accreditation Council for Continuing Medical Education

More information

10/15/2012. Lessons Learned from Tim Russert: Investigating Residual Risk. Tim Russert: Residual CV Risk?

10/15/2012. Lessons Learned from Tim Russert: Investigating Residual Risk. Tim Russert: Residual CV Risk? Lessons Learned from Tim Russert: Investigating Residual Risk Peter H. Jones, MD, FACP Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Houston, Texas Tim Russert:

More information

Placebo-Controlled Statin Trials

Placebo-Controlled Statin Trials PREVENTION OF CHD WITH LIPID MANAGEMENT AND ASPIRIN: MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of

More information

Metabolic Syndrome : Myth Of Reality. PD Khandelwal EVOLUTION OF METABOLIC SYNDROME

Metabolic Syndrome : Myth Of Reality. PD Khandelwal EVOLUTION OF METABOLIC SYNDROME Metabolic Syndrome : Myth Of Reality PD Khandelwal EVOLUTION OF METABOLIC SYNDROME After being given a series of names throughout the path of its evolution since 1922,when a Swedish physician named kylin

More information

Hypertriglyceridemia: Why, When, and How to Treat. Gregory Cohn, MD, FNLA, FASPC

Hypertriglyceridemia: Why, When, and How to Treat. Gregory Cohn, MD, FNLA, FASPC Hypertriglyceridemia: Why, When, and How to Treat Gregory Cohn, MD, FNLA, FASPC DISCLOSURES Consultant to Akcea Therapeutics (in the past 12 months). OUTLINE I. Lipoproteins II. Non-HDL-C III. Causes and

More information

Study of rhythm disturbances in acute myocardial infarction in Government Dharmapuri Medical College Hospital, Dharmapuri

Study of rhythm disturbances in acute myocardial infarction in Government Dharmapuri Medical College Hospital, Dharmapuri Original Research Article Study of rhythm disturbances in acute myocardial infarction in Government Dharmapuri Medical College Hospital, Dharmapuri P. Sasikumar * Department of General Medicine, Govt.

More information

Management of Post-transplant hyperlipidemia

Management of Post-transplant hyperlipidemia Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and

More information

Frequency of Dyslipidemia and IHD in IGT Patients

Frequency of Dyslipidemia and IHD in IGT Patients Frequency of Dyslipidemia and IHD in IGT Patients *Islam MS, 1 Hossain MZ, 2 Talukder SK, 3 Elahi MM, 4 Mondal RN 5 Impaired glucose tolerance (IGT) is often associated with macrovascular complications.

More information

Ketogenic Diets-good, bad, indifferent? Peter Clifton CSIRO Human Nutrition

Ketogenic Diets-good, bad, indifferent? Peter Clifton CSIRO Human Nutrition Ketogenic Diets-good, bad, indifferent? Peter Clifton CSIRO Human Nutrition Presenter Disclosure Information

More information

Serum Concentration of High-sensitivity CRP in Metabolic Syndrome A Case-control Study

Serum Concentration of High-sensitivity CRP in Metabolic Syndrome A Case-control Study Serum Concentration of High-sensitivity CRP in Metabolic Syndrome A Case-control Study Faisal Gh. Al-Rubaye (PhD; MSc)*, Hashim M. Hashim** Yahya Y Z. Farid (PhD)*, Kadhum Jumah (BSc)* Abstract Background:

More information

Obesity, metabolic dysfunction, and the risk of obesity-related cancer

Obesity, metabolic dysfunction, and the risk of obesity-related cancer Boston University OpenBU Theses & Dissertations http://open.bu.edu Boston University Theses & Dissertations 2016 Obesity, metabolic dysfunction, and the risk of obesity-related cancer Chadid, Susan https://hdl.handle.net/2144/16734

More information

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society

More information

CVD Prevention, Who to Consider

CVD Prevention, Who to Consider Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..

More information

1/28/2014. The Metabolic Syndrome: Early History. Insulin Resistance: Early Diagnosis and Treatment to Prevent Cardiovascular Disease

1/28/2014. The Metabolic Syndrome: Early History. Insulin Resistance: Early Diagnosis and Treatment to Prevent Cardiovascular Disease : Early Diagnosis and Treatment to Prevent Cardiovascular Disease Henry N. Ginsberg, M.D. Irving Professor of Medicine Columbia University College of Physicans and Surgeons The Metabolic Syndrome: Early

More information

Assessing Cardiovascular Disease Risk Factors in Overweight and Obese. Mexican-American Adults. Srijana Neupane

Assessing Cardiovascular Disease Risk Factors in Overweight and Obese. Mexican-American Adults. Srijana Neupane Assessing Cardiovascular Disease Risk Factors in Overweight and Obese Mexican-American Adults by Srijana Neupane A Thesis Presented in Partial Fulfillment of the Requirements for the Degree Master of Science

More information

Cedars Sinai Diabetes. Michael A. Weber

Cedars Sinai Diabetes. Michael A. Weber Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor

More information

Pattern of dyslipidemia and evaluation of non-hdl cholesterol as a marker of risk factor for cardiovascular disease in type 2 diabetes mellitus

Pattern of dyslipidemia and evaluation of non-hdl cholesterol as a marker of risk factor for cardiovascular disease in type 2 diabetes mellitus Original Article Nepal Med Coll J 2012; 14(4): 278-282 Pattern of dyslipidemia and evaluation of non-hdl cholesterol as a marker of risk factor for cardiovascular disease in type 2 diabetes mellitus A

More information

Metabolic Syndrome and Chronic Kidney Disease

Metabolic Syndrome and Chronic Kidney Disease Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference

More information

Introduction. Objectives. Psychotropic Medications & Cardiometabolic Risk

Introduction. Objectives. Psychotropic Medications & Cardiometabolic Risk Psychotropic Medications & Cardiometabolic Risk Sam Ellis, PharmD, BCPS, CDE Associate Professor University of Colorado School of Pharmacy Introduction Second GenerationAntipsychotics (SGA) first FDA approved

More information

Lipid Management: Beyond LDL

Lipid Management: Beyond LDL Lipid Management: Beyond LDL Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine University of Kentucky Overview Discuss the concept of residual risk Review current evidence-based medicine

More information

DOI: /01.CIR C6

DOI: /01.CIR C6 Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition Scott M. Grundy, H. Bryan Brewer,

More information

Myths, Heart Disease and the Latino Population. Maria T. Vivaldi MD MGH Women s Heart Health Program. Hispanics constitute 16.3 % of US population!

Myths, Heart Disease and the Latino Population. Maria T. Vivaldi MD MGH Women s Heart Health Program. Hispanics constitute 16.3 % of US population! Myths, Heart Disease and the Latino Population Maria T. Vivaldi MD MGH Women s Heart Health Program Hispanics constitute 16.3 % of US population! 1 LEADING CAUSES OF DEATH IN LATINOS Heart disease is the

More information

LDL cholesterol and cardiovascular outcomes?

LDL cholesterol and cardiovascular outcomes? LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary

More information

CARDIOVASCULAR RISK FACTORS IN AMERICAN INDIAN AND AFRICAN AMERICAN WOMEN OF CHILD BEARING AGE AND THE RELATIONSHIP OF THESE FACTORS TO BLOOD

CARDIOVASCULAR RISK FACTORS IN AMERICAN INDIAN AND AFRICAN AMERICAN WOMEN OF CHILD BEARING AGE AND THE RELATIONSHIP OF THESE FACTORS TO BLOOD CARDIOVASCULAR RISK FACTORS IN AMERICAN INDIAN AND AFRICAN AMERICAN WOMEN OF CHILD BEARING AGE AND THE RELATIONSHIP OF THESE FACTORS TO BLOOD LEPTIN CONCENTRATION, INSULIN RESISTANCE AND WAIST CIRCUMFERENCE

More information

Fructose in Insulin Resistance- Focused on Diabetes 순천향대학교부천병원 내분비내과 정찬희

Fructose in Insulin Resistance- Focused on Diabetes 순천향대학교부천병원 내분비내과 정찬희 Fructose in Insulin Resistance- Focused on Diabetes 순천향대학교부천병원 내분비내과 정찬희 Introduction Unique characteristics of Fructose Metabolism Mechanism for Fructose-Induced Insulin Resistance Epidemiological Studies

More information

Pasta: A High-Quality Carbohydrate Food

Pasta: A High-Quality Carbohydrate Food Pasta: A High-Quality Carbohydrate Food Cyril W.C. Kendall Department of Nutritional Sciences, Faculty of Medicine, University of Toronto; Clinical Nutrition & Risk Factor Modification Center, St. Michael

More information

The role of physical activity in the prevention and management of hypertension and obesity

The role of physical activity in the prevention and management of hypertension and obesity The 1 st World Congress on Controversies in Obesity, Diabetes and Hypertension (CODHy) Berlin, October 26-29 2005 The role of physical activity in the prevention and management of hypertension and obesity

More information

Non-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017

Non-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017 Non-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017 Historical Basis for Fasting Lipids The initial classifications of hyperlipidemia proposed in 1967 were genetic and required

More information

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t? Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial

More information

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were

More information

Disclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017

Disclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017 Disclosures MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES Grants: NIH, Quest Diagnostics Consultant: Quest Diagnostics Merck Global Atherosclerosis Advisory Board Ronald M. Krauss, Children s Hospital

More information

Obesity and the Metabolic Syndrome in Developing Countries: Focus on South Asians

Obesity and the Metabolic Syndrome in Developing Countries: Focus on South Asians Obesity and the Metabolic Syndrome in Developing Countries: Focus on South Asians Anoop Misra Developing countries, particularly South Asian countries, are witnessing a rapid increase in type 2 diabetes

More information

Early cardiovascular risk factors in South Asians

Early cardiovascular risk factors in South Asians Early cardiovascular risk factors in South Asians MINTU TURAKHIA, MD MAS Instructor of Medicine, Stanford University Director of Cardiac Electrophysiology, Palo Alto VA Research Chair, South Asian Heart

More information

FAPESP Week /21/2017

FAPESP Week /21/2017 Texas Tech University Dr Naima Moustaid-Moussa Texas Tech University FAPESP Week 2017 09/21/2017 University of Sao Paulo Dr Sonia Jancar ICB-USP Theresa Ramalho MS PhD candidate, Immunology ICB-USP Dr

More information

The metabolic syndrome has received increased attention

The metabolic syndrome has received increased attention AHA/NHLBI Scientific Statement Diagnosis and Management of the Metabolic Syndrome An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Scott M. Grundy, MD, PhD,

More information

Paraoxonase Responses to Exercise and Niacin Therapy in Men with Metabolic Syndrome. James Kyle Taylor

Paraoxonase Responses to Exercise and Niacin Therapy in Men with Metabolic Syndrome. James Kyle Taylor Paraoxonase Responses to Exercise and Niacin Therapy in Men with Metabolic Syndrome by James Kyle Taylor A dissertation submitted to the Graduate Faculty of Auburn University in partial fulfillment of

More information

Management Issues in the Metabolic Syndrome

Management Issues in the Metabolic Syndrome Review Article Management Issues in the Metabolic Syndrome PC Deedwania*, R Gupta** Abstract The metabolic syndrome or cardiovascular dysmetabolic syndrome is characterized by obesity, central obesity,

More information

Review Article A Comprehensive Review on Metabolic Syndrome

Review Article A Comprehensive Review on Metabolic Syndrome Hindawi Publishing Corporation Cardiology Research and Practice Volume 2014, Article ID 943162, 21 pages http://dx.doi.org/10.1155/2014/943162 Review Article A Comprehensive Review on Metabolic Syndrome

More information

Prediction of Homeostasis Model Assessment of Insulin Resistance in Japanese Subjects

Prediction of Homeostasis Model Assessment of Insulin Resistance in Japanese Subjects Tokai J Exp Clin Med., Vol. 37, No. 4, pp. 12-16, 212 Prediction of Homeostasis Model Assessment of Insulin Resistance in Japanese Subjects Masako NEGAMI, Eiko TAKAHASHI, Hiroki OTSUKA and Kengo MORIYAMA

More information

Clinical Practice Guidelines for Diabetes Management

Clinical Practice Guidelines for Diabetes Management Clinical Practice Guidelines for Diabetes Management Diabetes is a disease in which blood glucose levels are above normal. Over the years, high blood glucose damages nerves and blood vessels, which can

More information

TABLE 1. Comparison of WHO, NCEP ATP III, and IDF Definitions of the Metabolic Syndrome* Risk factors WHO 3 NCEP ATP III 6,7 IDF 8 DM/IFG or IGT or IR

TABLE 1. Comparison of WHO, NCEP ATP III, and IDF Definitions of the Metabolic Syndrome* Risk factors WHO 3 NCEP ATP III 6,7 IDF 8 DM/IFG or IGT or IR CONCISE REVIEW FOR METABOLIC CLINICIANS SYNDROME The Metabolic Syndrome: Concepts and Controversy LEWIS W. JOHNSON, MD, AND RUTH S. WEINSTOCK, MD, PHD The metabolic syndrome is an insulin-resistant state

More information

Bachelorarbeit Fructose and weight gain

Bachelorarbeit Fructose and weight gain Bachelorarbeit Fructose and weight gain Bogner-Strauß, Juliane Gertrude, Assoc.Prof. Mag.rer.nat. Dr.rer.nat. Von Johanna Maria Ticar Mat: 0730208 Graz, 27.07.2011 Abstract The prevalence of obesity is

More information

Nutrition and Medicine, 2006 Tufts University School of Medicine Nutrition and Type 2 Diabetes: Learning Objectives

Nutrition and Medicine, 2006 Tufts University School of Medicine Nutrition and Type 2 Diabetes: Learning Objectives Nutrition and Medicine, 2006 Tufts University School of Medicine Nutrition and Type 2 Diabetes: Learning Objectives Margo N. Woods, D.Sc. 1. Discuss the increase in the incidence and prevalence of type

More information

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary

More information

Diabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome

Diabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome Diabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome John E. Nestler, M.D. William Branch Porter Professor of Medicine Chair, Department of Internal Medicine Virginia Commonwealth University

More information

Developing nations vs. developed nations Availability of food contributes to overweight and obesity

Developing nations vs. developed nations Availability of food contributes to overweight and obesity KNH 406 1 Developing nations vs. developed nations Availability of food contributes to overweight and obesity Intake Measured in kilojoules (kj) or kilocalories (kcal) - food energy Determined by bomb

More information

J Clin Endocrin Metab. First published ahead of print July 29, 2008 as doi: /jc

J Clin Endocrin Metab. First published ahead of print July 29, 2008 as doi: /jc J Clin Endocrin Metab. First published ahead of print July 29, 2008 as doi:10.1210/jc.2008-0222 Title: Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An

More information